




Society leads SEK 87 million financing round in Neogap Therapeutics

Society has led a SEK 87 million financing round for Neogap Therapeutics, a Swedish clinical-stage biotech company developing personalised immunotherapy for cancer. The capital will be used to advance the company's ongoing Phase I/II clinical trial and build the clinical data required for the next stage of development. Society has also invested its own capital in the round, in line with its role as a long-term capital partner.



Neogap is developing pTTL (personalised Tumour Trained Lymphocytes), a personalised cell-based immunotherapy in which the patient's own T cells are trained to recognise and attack tumour cells based on the patient's unique neoantigens. The selection of relevant neoantigens is supported by advanced bioinformatics and AI-driven analyses of the tumour's genetic profile.

The therapy is based on the company's patented PIOR[®] and EpiTCer[®] technologies and is currently being evaluated in a Phase I/II clinical trial in colorectal cancer at several Swedish hospitals. The primary objective of the trial is to evaluate the safety and tolerability of the treatment and to collect initial data on treatment response.

Since the previous financing round in 2023, Neogap has reached several important milestones. The company has treated the first patients in the trial and presented positive initial safety data. In addition, Neogap has received approval from the Swedish Medical Products Agency to administer full doses to all patients in the trial, enabling a more flexible and efficient trial design. As part of its EIC grant, Neogap has, in collaboration with CDMO NorthX Biologics, developed a manufacturing framework for later-stage clinical trials and future commercialisation.

Colorectal cancer is the third most common form of cancer globally, with approximately 2 million new cases each year. Despite this, there are currently few effective treatment options for patients with advanced disease. The colorectal cancer therapeutics market was estimated at approximately USD 9 billion in 2024 across the seven major pharmaceutical markets (7MM). Based on available market data, pTTL is estimated to have potential annual revenue in the range of USD 1.4–1.9 billion.

"Neogap is at a stage where clear progress is combined with strong commercial potential in an area of significant unmet medical need. The company has a unique therapeutic approach to T-cell therapy, combining personalised treatment with a scalable manufacturing process. This is exactly the type of company we focus on when we invest and raise capital," says Andreas Lindblom, Managing Partner at Sciety.

"The capital enables us to continue the clinical development of pTTL within our ongoing clinical trial and take the next step in the programme. Over the past year, we have made clear progress in both the clinical and manufacturing areas, and we look forward to advancing it further," says Samuel Svensson, CEO of Neogap Therapeutics.

For more information, please contact:

Andreas Lindblom, Managing Partner, Sciety
andreas.lindblom@sciety.se | +46 70 375 73 73

Samuel Svensson, CEO, Neogap Therapeutics
samuel.svensson@neogap.se | +46 733 54 21 94

About Sciety

Sciety is a long-term investment partner and investor in life science and health tech, with a focus on the Nordic region. We identify and invest in growth companies with the potential to create significant value for both investors and society, and with a clear path towards a future exit. We lead investment processes and invest alongside leading venture capital firms, family offices, and through our investor network, Sciety Venture Partners. Our goal is for growth companies within life science and digital health to scale and succeed, making scientific breakthroughs in medicine and technology accessible to people all over the world. For more information, visit www.sciety.com and follow us on [LinkedIn](#).

About Neogap Therapeutics

Neogap Therapeutics is a Swedish clinical-stage biotechnology company developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two proprietary technologies, PIOR® and EpiTCer®. PIOR® leverages patient-derived DNA sequencing data and machine learning to identify tumour-specific mutations. EpiTCer® is used to expand T cells that recognise and target the selected tumour-specific structures. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its research, please visit neogap.se and follow us on [LinkedIn](#).